Rubella

For medical students2 min readUpdated 2026-10-10

Rubella is an acute viral anthropnotic infection transmitted via airborne droplets and transplacental routes. It is characterized by a maculopapular rash, lymphadenopathy, and extreme teratogenic risk to the developing fetus if contracted during pregnancy.

PathogenAn unstable virus in the environment requiring close contact for transmission.

ReservoirHumans only (infected individuals or infants with congenital rubella).

IncubationAverage 16–21 days (range: 11 to 24 days).

Outbreak RiskOccurs when ≥ 15% of the population lacks immunity.

ImmunityLong-lasting, lifelong immunity following natural infection.

Epidemiology

Rubella is a strict anthroponosis, with humans serving as the sole reservoir. This includes patients with clinical or subclinical infections, as well as infants with congenital rubella syndrome.

An infected individual is most contagious during the second half of the incubation period and for one week after the rash appears. Infants with congenital rubella can shed the virus in urine, stool, and nasopharyngeal secretions for prolonged periods—up to two years. Notably, viral strains shed by these infants exhibit higher virulence, serving as a source of droplet transmission to contacts.

Main transmission routes:

Airborne droplets — The primary mechanism of transmission via close contact with an infected person. The virus is labile in the external environment, rendering its contagiousness lower than that of measles or varicella. Prolonged and close contact is required for transmission.
Transplacental (vertical) — Transmission from an infected pregnant mother to the developing fetus.

Outbreaks typically occur in cyclical patterns, particularly in pediatric settings. Epidemic surges emerge when the proportion of non-immune individuals in a population reaches or exceeds 15%.

Clinical Forms

The infection presents in two primary forms that differ significantly in their transmission mechanism and clinical manifestations: acquired and congenital. Overall, the rubella virus causes three distinct pathological states:

Acquired rubella (classic clinical presentation).
Congenital rubella (result of fetal infection).
Progressive rubella panencephalitis (a severe late complication).

Infection confers robust, lifelong immunity regardless of the clinical form experienced.

Pathogenesis and Clinical Presentation of Acquired Rubella

The virus enters the body via the upper respiratory tract mucosa, where primary replication occurs in regional lymph nodes. The pathogen then enters the bloodstream (viremia phase), disseminates throughout the body, and localizes in lymph nodes and skin epithelium. The characteristic rash is the result of an immune-mediated inflammatory reaction in the skin.

The clinical course progresses sequentially:

Incubation period lasts from 11 to 24 days.
Prodromal period features mild catarrhal symptoms, conjunctivitis, and low-grade fever.
Pathognomonic sign — enlargement of the suboccipital and posterior cervical lymph nodes.
Exanthem period is characterized by a generalized maculopapular rash.

In children, the infection is typically mild. Viremia resolves within two days after rash onset, but the virus can persist in upper respiratory secretions for up to two weeks. Complications can occasionally include arthritis, meningitis, encephalitis, or thrombocytopenic purpura.

Serological Diagnosis

The acute infection induces a transient secondary cell-mediated immunodeficiency. Serological markers are utilized to diagnose acute infection and assess immune status:

Anti-hemagglutinins and virus-neutralizing antibodies — High titers indicate protection and persist for life.
Complement-fixing antibodies — Circulate in the blood for only a few years; thus, their detection indicates a recent infection.

Mnemonic

Posterior cervical and suboccipital lymphadenopathy is a hallmark of rubella. Picture 'rubella nodes' swelling up at the back of the neck.

Frequently asked questions

What is the classification and structure of the rubella pathogen?

The rubella pathogen is an RNA-containing virus, the sole member of the genus Rubivirus within the family Togaviridae. The virion is spherical (60–70 nm in diameter) and contains a single-stranded linear (+)-sense RNA genome.

Viral structure includes:

Supercapsid (envelope) — A lipid bilayer studded with viral envelope glycoproteins E1 (hemagglutinin, a major immunogen) and E2 (mediates cell receptor binding).
Nucleocapsid — Located internally, composed of genomic RNA and structural non-glycosylated C-protein.

The viral genome also encodes two non-structural proteins (NS1 and NS2).

What congenital defects comprise the classic Gregg syndrome in congenital rubella?

Classic Gregg syndrome (congenital rubella syndrome) features a characteristic triad of severe fetal developmental anomalies resulting from early intrauterine infection.

This triad comprises:

Ocular pathology — Most commonly cataracts (a classic sign), along with glaucoma, microphthalmia, and chorioretinitis.
Congenital heart defects — Patent ductus arteriosus (PDA), pulmonary artery stenosis, ventricular septal defects, and atrial septal defects.
Deafness — Caused by structural malformations of the inner ear.

What are the clinical manifestations and features of progressive rubella panencephalitis?

Progressive rubella panencephalitis (PRP) is a rare slow virus infection resulting from persistent viral infection within the central nervous system.

Features and clinical manifestations:

Onset — Manifests in the second decade of life in individuals who had acquired infection in childhood or in children with congenital rubella.
Clinical picture — Characterized by progressive cognitive decline and motor dysfunction of the central nervous system.
Prognosis — Unfavorable, culminating in death.
Epidemiological significance — Affected individuals are completely non-contagious because the virus is absent from their bodily secretions.

What specific prophylaxis and vaccination strategies are used against rubella?

Specific prophylaxis of rubella relies on live attenuated viral vaccines.

Combined vaccines, such as the measles, mumps, and rubella (MMR) vaccine, are routinely administered.

Standard immunization schedules typically recommend the first dose at 12–15 months of age, with a booster dose administered during early childhood. Additional catch-up immunization targets unvaccinated, non-infected, or partially immunized children and adolescents, as well as non-immune women of childbearing age.

The primary goal of prophylaxis is to protect pregnant women and prevent congenital rubella syndrome.

Why is the contagiousness of rubella lower than that of measles?

This is due to the lability of the rubella virus in the external environment. Successful transmission requires prolonged and close contact with the infection source.

Which biological fluids are infectious?

The virus is shed in upper respiratory secretions, urine, and feces.

How long are infants with congenital rubella contagious?

Infants with congenital rubella can shed the virus into the environment for a very long time—up to 2 years.

What proportion of susceptible population triggers an outbreak?

An epidemic increase in morbidity occurs when the proportion of individuals lacking immunity to the virus reaches 15% or higher.

Go deeper

Pathophysiology of congenital rubella
Specific manifestations of congenital rubella syndrome
Mechanism of progressive rubella panencephalitis
Differential diagnosis of rashes: rubella, measles, and scarlet fever
Specific vaccination schedules for rubella prevention